Rankings
▼
Calendar
SUPN Q3 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q3 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$176M
+14.2% YoY
Gross Profit
$158M
90.0% margin
Operating Income
$41M
23.2% margin
Net Income
$38M
21.9% margin
EPS (Diluted)
$0.69
QoQ Revenue Growth
+4.4%
Cash Flow
Operating Cash Flow
$54M
Free Cash Flow
$53M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$336M
Stockholders' Equity
$1.0B
Cash & Equivalents
$32M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$176M
$154M
+14.2%
Gross Profit
$158M
$134M
+17.7%
Operating Income
$41M
$8M
+401.9%
Net Income
$38M
-$16M
+341.0%
Revenue Segments
Product
$170M
49%
Qelbree
$62M
18%
GOCOVRI
$36M
10%
Oxtellar X R
$30M
9%
APOKYN
$20M
6%
Trokendi Xr
$15M
4%
Manufactured Product, Other
$7M
2%
Royalty, License And Other Revenue
$5M
2%
← FY 2024
All Quarters
Q4 2024 →